---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-23-000004"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2023-01-23T23:59:59+00:00"
generated_at: "2026-06-20T11:33:38.410146+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Exagen appoints Tina S. Nova, Ph.D. as Executive Chair, effective Jan 19, 2023

## Summary
- Dr. Nova replaces Brian Birk, who remains on the Board.
- Nova is President of Veracyte's U.S. CLIA business; former CEO of Decipher Biosciences.
- Nova co-founded Genoptix (sold to Novartis for $470M) and held leadership at Illumina.
- Company says her experience will help expand its position in autoimmune testing.

## SEC filing metadata
- accession: 0001274737-23-000004
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2023-01-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473723000004/0001274737-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473723000004/exdx-20230123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-23-000004
- JSON: https://secwatch.observer/filing/0001274737-23-000004.json
- Plain text: https://secwatch.observer/filing/0001274737-23-000004.txt

## Key facts
- Governance Changes
  EXAGEN INC.: Adopted amendment to bylaws to allow Board to appoint an executive chairperson of the Board, who shall also be chairperson of the Board and an officer of the Company, and to empower the executive chairperson to appoint other officers and agents as the business may require (effective 2023-01-19).
  - Change: bylaw amendment
  - Effective: 2023-01-19
  source text: On January 19, 2023, the board of directors (the “Board”) of Exagen Inc. (the “Company”) adopted an amendment (the “Bylaws Amendment”) to the amended and restated bylaws of the Company to provide that the Board may appoint from its members an executive chairperson of the Board and that the executive chairperson, if any, shall also be the chairperson of the Board and an officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1274737/000127473723000004/0001274737-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.